Leerink Partnrs Analysts Boost Earnings Estimates for Nkarta

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Stock analysts at Leerink Partnrs raised their Q1 2025 EPS estimates for shares of Nkarta in a research report issued to clients and investors on Wednesday, March 26th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings per share of ($0.46) for the quarter, up from their previous forecast of ($0.51). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.44) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.66) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at ($1.34) EPS.

A number of other equities research analysts also recently weighed in on the stock. Stifel Nicolaus dropped their target price on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 27th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Nkarta in a research report on Thursday, March 27th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $14.86.

Nkarta Price Performance

Shares of NASDAQ:NKTX traded down $0.20 on Monday, hitting $1.71. The company's stock had a trading volume of 1,089,495 shares, compared to its average volume of 1,096,627. Nkarta has a 1 year low of $1.31 and a 1 year high of $10.16. The company has a market capitalization of $121.34 million, a PE ratio of -0.91 and a beta of 0.83. The company has a 50-day simple moving average of $1.94 and a 200 day simple moving average of $2.75.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06.

Institutional Trading of Nkarta

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Erste Asset Management GmbH bought a new position in shares of Nkarta in the third quarter worth approximately $33,000. Invesco Ltd. purchased a new position in shares of Nkarta in the fourth quarter valued at about $30,000. Sequoia Financial Advisors LLC bought a new position in shares of Nkarta during the fourth quarter valued at about $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Nkarta during the fourth quarter worth about $37,000. Finally, Intech Investment Management LLC bought a new stake in shares of Nkarta in the third quarter worth about $74,000. Institutional investors own 80.54% of the company's stock.

Insider Activity

In related news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This represents a 5.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 8.70% of the company's stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.